ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans (Q51472167)

5 April 2018

title

ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans (English)

1 reference

5 April 2018

author name string

Leo Widler

2

1 reference

5 April 2018

Rainer Gamse

3

1 reference

5 April 2018

Thomas Buhl

4

1 reference

5 April 2018

Klaus Seuwen

5

1 reference

5 April 2018

Werner Breitenstein

6

1 reference

5 April 2018

Rossella Belleli

8

1 reference

5 April 2018

Michaela Kneissel

10

1 reference

5 April 2018

Markus R. John

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21514409

30 November 2024

Gerard J. M. Bruin

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21514409

30 November 2024

Lloyd B. Klickstein

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21514409

30 November 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21514409

30 November 2024

publication date

14 April 2011

1 reference

5 April 2018

full work available at URL

https://api.elsevier.com/content/article/PII:S875632821100929X?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2011.04.007

https://api.elsevier.com/content/article/PII:S875632821100929X?httpAccept=text/plain

30 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2011.04.007

30 November 2024

1 reference

5 April 2018

volume

49

1 reference

5 April 2018

issue

2

1 reference

5 April 2018

page(s)

233-241

1 reference

5 April 2018

Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2011.04.007

Anti-resorptives in the management of osteoporosis

30 November 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2011.04.007

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

30 November 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2011.04.007

A comprehensive review of treatments for postmenopausal osteoporosis

30 November 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2011.04.007

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

30 November 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2011.04.007

Update of current therapeutic options for the treatment of postmenopausal osteoporosis

30 November 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2011.04.007

The anabolic effects of parathyroid hormone

30 November 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2011.04.007

Anabolic actions of parathyroid hormone on bone

30 November 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2011.04.007

Parathyroid hormone signaling in bone and kidney

30 November 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2011.04.007

Studies on the mechanisms of the skeletal anabolic action of endogenous and exogenous parathyroid hormone

30 November 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2011.04.007

Parathyroid hormone: a double-edged sword for bone metabolism

30 November 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2011.04.007

Molecular and cellular mechanisms of the anabolic effect of intermittent PTH

30 November 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2011.04.007

Does osteocytic SOST suppression mediate PTH bone anabolism?

30 November 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2011.04.007

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

30 November 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2011.04.007

Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis

30 November 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2011.04.007

Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment

30 November 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2011.04.007

Efficacy and Safety of Human Parathyroid Hormone-(1–84) in Increasing Bone Mineral Density in Postmenopausal Osteoporosis

30 November 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2011.04.007

Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial

30 November 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2011.04.007

Effects of Intermittent Parathyroid Hormone Administration on Bone Mineralization Density in Iliac Crest Biopsies from Patients with Osteoporosis: A Paired Study before and after Treatment

30 November 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2011.04.007

Safety of parathyroid hormone for the treatment of osteoporosis

30 November 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2011.04.007

Delivery of parathyroid hormone for the treatment of osteoporosis

30 November 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2011.04.007

The search for calcium receptor antagonists (calcilytics).

30 November 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2011.04.007

Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats

30 November 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2011.04.007

An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation

30 November 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2011.04.007

1-Alkyl-4-phenyl-6-alkoxy-1H-quinazolin-2-ones: a novel series of potent calcium-sensing receptor antagonists

30 November 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2011.04.007

Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate

30 November 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2011.04.007

Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers

30 November 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2011.04.007

The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis

30 November 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2011.04.007

Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men.

30 November 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2011.04.007

Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial

30 November 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2011.04.007

Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis.

30 November 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2011.04.007

An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis

30 November 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2011.04.007

Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.

30 November 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2011.04.007

Parathyroid hormone as an anabolic skeletal therapy

30 November 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2011.04.007

Rapid and robust response of biochemical markers of bone formation to teriparatide therapy

30 November 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2011.04.007

Plasma levels of parathyroid hormone that induce anabolic effects in bone of ovariectomized rats can be achieved by stimulation of endogenous hormone secretion

30 November 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2011.04.007

Reconstructing the skeleton with intermittent parathyroid hormone

30 November 2024

38

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2011.04.007

The Effects of Programmed Administration of Human Parathyroid Hormone Fragment (1–34) on Bone Histomorphometry and Serum Chemistry in Rats*

30 November 2024

40

1 reference

https://api.crossref.org/works/10.1016/J.BONE.2011.04.007

30 November 2024

Identifiers

1 reference

5 April 2018

1 reference

5 April 2018